Jan Robison

Jan Robison

biostrategy

BSc in Biotechnology, learning finance while traveling Investor's Biker’s style, without the bike.

Recent articles


Eli Lilly: Fasten Your Seat Belts for a Bumpy Ride

Eli Lilly is facing a perfect storm. Its lead product, the antidepressant Cymbalta will lose its U.S. patent exclusivity this week while its late stage phase 3 wildcating has been producing dry holes.


Orexigen Therapeutics: Light at the End of the Tunnel?

Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?



Seattle Genetics Is Down but Not Out

Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.